High prevalence of Helicobacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong

Alimentary Pharmacology and Therapeutics

Volumn 14, Issue 7, 2000, Pages 901-910

  Wang, W H ^a   Wong, B C Y ^a   Mukhopadhyay, A K ^b   Berg, D E ^b   Cho, C H ^a   Lai, K C ^a   Hu, W H C ^a   Fung, F M Y ^a   Hui, W M ^a   Lam, S K ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; METRONIDAZOLE; RIBOSOME RNA;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM CULTURE; BACTERIUM MUTANT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA FINGERPRINTING; ENDOSCOPIC BIOPSY; ERADICATION THERAPY; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HONG KONG; HUMAN; HUMAN TISSUE; MINIMUM INHIBITORY CONCENTRATION; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STOMACH BIOPSY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, MULTIPLE; FEMALE; GENE FREQUENCY; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HONG KONG; HUMANS; MALE; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; POINT MUTATION; RNA, RIBOSOMAL, 23S;

EID: 0033922945     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2000.00795.x     Document Type: Article

References (34)

1. 1 Dunn BE, Cohen H, Blaser MJ. Helicobacter pylori. Clin Microbiol Rev 1997; 10: 720-41.
2. 2 Lambert JR, Lin SK, Michel AJ. Helicobacter pylori. Scan J Gastroenterol 1995; 30(Suppl. 208): 33-46.
3. 3 Eslick GD, Lim LL, Byles JE, Xia HH, Talley NJ. Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis. Am J Gastroenterol 1999; 94: 2373-9.
4. 4 Wong BCY, Xiao SD, Hu FL, et al. Comparison of lasoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer: an Asian multi-center prospective double blind randomized placebo controlled study. Aliment Pharmacol Ther 2000; 14: 217-24.
5. 5 Chu KM, Choi HK, Tuen HH, Law SY, Branicki FJ, Wong J. A prospective randomized trial comparing the use of omeprazole-based dual and triple therapy for eradication of Helicobacter pylori. Am J Gastroenterol 1998; 93: 1436-42.
6. 6 Midolo PD, Lambert JR, Turnbridge J. Metronidazole resistance: predictor of failure of Helicobacter pylori eradication by triple therapy. J Gastroenterol Hepatol 1996; 11: 290-2.
7. 7 Buckley MJ, Xia HX, Hyde DM, Keane CT, O'Morain CA. Metronidazole resistance reduces efficacy of triple therapy and leads to secondary clarithromycin resistance. Dig Dis Sci 1997; 42: 2111-5.
8. 8 Miyaji H, Azuma T, Ito S, Suto H, Ito Y, Yamazaki Y. Susceptibility of Helicobacter pylori isolates to metronidazole, clarithromycin and amoxycillin in vitro and in clinical treatment in Japan. Aliment Pharmacol Ther 1997; 11: 1131-6.
9. 9 Megraud F. Antibiotic resistance in Helicobacter pylori infection. Br Med Bull 1998; 54: 207-16.
10. 10 Vakil N, Hahn B, McSorley D. Clarithromycin-resistant Helicobacter pylori in patients with duodenal ulcer in the United States. Am J Gastroenterol 1998; 93: 1432-5.
11. 11 Xia HX, Keane CT, O'Morain CAA. 5-year survey of metronidazole and clarithromycin resistance in clinical isolates of Helicobacter pylori. Gut 1996; 39(Suppl. 2): A6-7(Abstract).
12. 12 Wong BCY, Lam SK, Ching CK. Differential Helicobacter pylori infection rates in two contrasting gastric cancer risk regions of South China. J Gastroenterol Hepatol 1999; 14: 120-5.
13. 13 Glupczynski Y. Antimicrobial resistance in Helicobacter pylori: a global overview. Acta Gastroenterol Belg 1998; 61: 357-66.
14. 14 National Committee for Clinical Laboratory Standards (NCCLS). Performance standards for antimicrobial susceptibility testing, Fourth Information Supplement. NCCLS Document M100-S4. Villanova, PA, 1992.
15. 15 Ausubel FM, Brent R, Kingston RE, et al. Current Protocols in Molecular Biology New York: Greene Publishing and Wiley Interscience, 1994.
16. 16 Versalovic J, Shortridge D, Kibler K, et al. Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob Agents Chemother 1996; 40: 477-80.
17. 17 Akopyanz N, Bukanov NO, Westblom TU, Kresovich S, Berg DE. DNA diversity among clinical isolates of Helicobacter pylori detected by PCR-based RAPD fingerprinting. Nucl Acids Res 1992; 20: 5137-42.
18. 18 Metzler CM, DeHaan RM. Susceptibility tests of anaerobic bacteria: statistical and clinical considerations. J Infect Dis 1974; 130: 588-94.
19. 19 Cederbrant G, Kahlmeter G, Ljungh A. The E test for antimicrobial susceptibility testing of Helicobacter pylori. J Antimicrobial Chemother 1993; 31: 65-71.
20. 20 Ching CK, Leung KP, Yung RWH, Lam SK, Wong BCY, Lai KC. Prevalence of metronidazole resistant Helicobacter pylori strains among Chinese peptic ulcer disease patients and normal controls in Hong Kong. Gut 1996; 38: 675-8.
21. 21 Katelaris PH, Nguyen TV, Robertson GJ, Bradbury R, Ngu MC. Prevalence and demographic determinants of metronidazole resistance by Helicobacter pylori in a large cosmopolitan cohort of Australian dyspeptic patients. Aust N Z J Med 1998; 28: 633-8.
22. 22 Glupeznski Y, Burrette A, Dekoster E, Nust JF, Deltenre M, Cadranel S. Metronidazole resistance in Helicobacter pylori. Lancet 1990; 335: 976-7.
23. 23 Ling TK, Cheng AF, Sung JJ, Yiu PY, Chung SS. An increase in Helicobacter pylori strains resistant to metronidazole: a five-year study. Helicobacter 1996; 1: 57-61.
24. 24 Osato MS, Reddy R, Graham DY. Metronidazole and clarithromycin resistance among Helicobacter pylori isolates from a large metropolitan hospital in the United States. Int J Antimicrob Agents 1999; 12: 341-7.
25. 25 Versalovic J, Osato MS, Spakovsky K, et al. Point mutation in the 23S rRNA gene of Helicobacter pylori associated with different levels of clarithromycin resistance. J Antimicrob Chemother 1997; 40: 283-6.
26. 26 Xia HX, Buckley M, Keane CT, O'Morain CA. Clarithromycin resistance in Helicobacter pylori: Prevalence in untreated dyspeptic patients and stability in vitro. J Antimicrob Chemother 1996; 37: 473-81.
27. 27 Wang GE, Rahman MS, Humayun MZ, Taylor DE. Multiplex sequence analysis demonstrates the competitive growth advantage of the A-to-G mutants of clarithromycin-resistant Helicobacter pylori. Antimicrob Agents Chemother 1999; 43: 683-5.
28. 28 Hulten K, Gibreel A, Skold O, Engstrand L. Macrolide resistance in Helicobacter pylori: mechanism and stability in strains from clarithromycin-treated patients. Antimicrob Agents Chemother 1997; 41: 2550-3.
29. 29 Dore MP, Osato MS, Kwon Dh, Graham DY, El-Zaatari FAK. Demonstration of unexpected antibiotic resistance of genotypically identical Helicobacter pylori isolates. Clin Infect Dis 1998; 27: 84-9.
30. 30 Graham DY. Antibiotic resistance in Helicobacter pylori: implication for therapy. Gastroenterology 1998; 115: 1272-7.
31. 31 Owen RJ, Slater ER, Gibson J, Lorenz E, Tompkins DS. Effect of clarithromycin and omeprazole therapy on the diversity and stability of genotypes of Helicobacter pylori from duodenal ulcer patients. Microb Drug Resist 1999; 5: 141-6.
32. 32 Miyaji H, Azuma T, Ito S, Sato H, Ito Y, Yamazaki Y. Susceptibility of Helicobacter pylori isolates to metronidazole, clarithromycin and amoxicillin in vitro and in clinical treatment in Japan. Aliment Pharmacol Ther 1997; 11: 1131-6.
33. 33 O'Riordan T, Mathai E, Tobin E. Adjuvant antibiotic therapy in duodenal ulcer treatment with colloidal bismuth subcitrate. Gut 1990; 31: 999-1002.
34. 34 Fok TF, Lau SP, Fung KP. Cord blood G-6-PD activity by quantitative enzyme assay and fluorescent spot test in Chinese neonates. Aust Paediatr J 1985; 21: 23-5.